News & Updates
Filter by Specialty:
Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
In untreated myelofibrosis, using navitoclax in combination with ruxolitinib appears to result in a twofold increase in the number of patients experiencing spleen volume shrinkage, regardless of prognosis, according to updated data from the phase III TRANSFORM-1 trial.
Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
17 Aug 2024
Adjunctive brexpiprazole benefits seen in Asian adults with MDD in real-world
Up to 3 months of treatment with adjunctive brexpiprazole helps with symptom severity in Asian adults with major depressive disorder (MDD) and inadequate response to antidepressants in a real-life clinical setting in Singapore.
Adjunctive brexpiprazole benefits seen in Asian adults with MDD in real-world
15 Aug 2024
Sildenafil shows promise as treatment for Alzheimer’s disease
Sildenafil, a phosphodiesterase type 5 inhibitor, can be a potential treatment for Alzheimer’s disease (AD), as shown in real-world data, AD patient-induced pluripotent stem cells (iPSC)-derived neuron models, and in vivo transgenic mouse model observations, according to a study presented at AAIC 2024.
